Veronika Groh

Veronika Groh

Auto-generated profile, based on publicly available information

Veronika Groh

Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA 98109, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2002 in Nature
Verified
Journal Article
Closed access
PDF file
VGVeronika Groh
Veronika Groh
JWJennifer Wu
Jennifer Wu
CYCassian Yee
Cassian Yee
TSThomas Spies
Thomas Spies

16 March 2009 in Journal of Experimental Medicine
Verified
Journal Article
Open access
ZDZhenpeng Dai
Zhenpeng Dai
CTCameron J. Turtle
Cameron J. Turtle
GBGarrett C. Booth
Garrett C. Booth
SRStanley R. Riddell
Stanley R. Riddell
TGTheodore A. Gooley
Theodore A. Gooley
VGVeronika Groh
Veronika Groh
The NKG2D receptor stimulates natural killer cell and T cell responses upon engagement of ligands associated with malignancies and certain autoimmune diseases. However, conditions of persistent NKG2D ligand expression can lead to immunosuppression. In cancer patients, tumor expression and shedding of the MHC class I–related chain A (MICA) ligand of NKG2D drives proliferative expansions of NKG2D+CD4+ T cells that produce interleukin-10 (IL-10) and transforming growth factor-β, as well as Fas ligand, which inhibits bystander T cell proliferation in vitro. Here, we show that increased frequencies of functionally equivalent NKG2D+CD4+ T cells are inversely correlated with disease activity in juvenile-onset systemic lupus erythematosus (SLE), suggesting that these T cells may have regulatory effects. The NKG2D+CD4+ T cells correspond to a normally occurring small CD4 T cell subset that is autoreactive, primed to produce IL-10, and clearly distinct from proinflammatory and cytolytic CD4 T cells with cytokine-induced NKG2D expression that occur in rheumatoid arthritis and Crohn's disease. As classical regulatory T cell functions are typically impaired in SLE, it may be clinically significant that the immunosuppressive NKG2D+CD4+ T cells appear functionally uncompromised in this disease.

11 April 2005 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
VGVeronika Groh
Veronika Groh
YLYongqing Q. Li
Yongqing Q. Li
DCDaniel Cioca
Daniel Cioca
NHNaomi N. Hunder
Naomi N. Hunder
WWWei Wang
Wei Wang
TSThomas Spies
Thomas Spies
Dendritic cells (DCs) have the capacity to prime tumor-specific T cell responses and are considered as potentially effective vaccines for immunotherapy of cancer. Critical parameters in the development of DC vaccines are the source of tumor antigen (TA) and the mode of DC-loading. Whole tumor cells contain complex assortments of TA, which has been exploited to enhance cross-presentation to CD8 T cells by DCs loaded with anti-syndecan mAb-opsonized myeloma cells. This approach may be broadly improved by targeting the MHC class I chain-related protein A (MICA), which is frequently and abundantly expressed on most if not all types of epithelial cancers but not in normal tissues except intestinal mucosa. Loading of DC with anti-MICA mAb-coated breast, melanoma, or ovarian tumor lines or uncultured ovarian cancer cells efficiently promoted TA cross-presentation and priming of multivalent anti-tumor CD8 and CD4 T cell responses. These were of substantially greater breadth and magnitude than those of T cells primed by peptide-pulsed or apoptotic tumor cell-loaded DCs. These results may advance DC vaccine development and provide a platform for adoptive T cell therapy and TA discovery. These results further suggest that antibody targeting of MICA might be applicable to elicit T cell immunity against tumors of diverse tissue origins in cancer patients.

23 May 2011 in BMC Cancer
Verified
Journal Article
Open access
PDF file
XXXiulong Xu
Xiulong Xu
GRGeetha S Rao
Geetha S Rao
VGVeronika Groh
Veronika Groh
TSThomas Spies
Thomas Spies
PGPaolo Gattuso
Paolo Gattuso
RPRichard Prinz
Richard Prinz
Major histocompatibility complex class I-related chain A and B (MICA/B) are two stress-inducible ligands that bind the immunoreceptor NKG2D and play an important role in mediating the cyotoxicity of NK and T cells. In this study, we sought to study MICA/B expression in pancreatic cancer and to determine whether and how genotoxic drugs such as gemcitabine can affect MICA/B expression and natural killer cytotoxity.

15 November 2010 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
NHNobuyoshi Hanaoka
Nobuyoshi Hanaoka
BJBana Jabri
Bana Jabri
ZDZhenpeng Dai
Zhenpeng Dai
CCCezary Ciszewski
Cezary Ciszewski
ASAnne M. Stevens
Anne M. Stevens
VGVeronika Groh
Veronika Groh
Deficiencies of the T cell and NK cell CD3ζ signaling adapter protein in patients with cancer and autoimmune diseases are well documented, but mechanistic explanations are fragmentary. The stimulatory NKG2D receptor on T and NK cells mediates tumor immunity but can also promote local and systemic immune suppression in conditions of persistent NKG2D ligand induction that include cancer and certain autoimmune diseases. In this paper, we provide evidence that establishes a causative link between CD3ζ impairment and chronic NKG2D stimulation due to pathological ligand expression. We describe a mechanism whereby NKG2D signaling in human T and NK cells initiates Fas ligand/Fas-mediated caspase-3/-7 activation and resultant CD3ζ degradation. As a consequence, the functional capacities of the TCR, the low-affinity Fc receptor for IgG, and the NKp30 and NKp46 natural cytotoxicity receptors, which all signal through CD3ζ, are impaired. These findings are extended to ex vivo phenotypes of T and NK cells among tumor-infiltrating lymphocytes and in peripheral blood from patients with juvenile-onset lupus. Collectively, these results indicate that pathological NKG2D ligand expression leads to simultaneous impairment of multiple CD3ζ-dependent receptor functions, thus offering an explanation that may be applicable to CD3ζ deficiencies associated with diverse disease conditions.